CSL Ltd
ASX:CSL
CSL Ltd
Revenue
CSL Ltd
Revenue Peer Comparison
Competitive Revenue Analysis
Latest Figures & CAGR of Competitors
Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
CSL Ltd
ASX:CSL
|
Revenue
$14.2B
|
CAGR 3-Years
12%
|
CAGR 5-Years
11%
|
CAGR 10-Years
10%
|
|
Immutep Ltd
ASX:IMM
|
Revenue
AU$256.6k
|
CAGR 3-Years
-61%
|
CAGR 5-Years
-45%
|
CAGR 10-Years
-24%
|
|
Mesoblast Ltd
ASX:MSB
|
Revenue
$7.5m
|
CAGR 3-Years
-23%
|
CAGR 5-Years
-14%
|
CAGR 10-Years
N/A
|
|
Clinuvel Pharmaceuticals Ltd
ASX:CUV
|
Revenue
AU$87.3m
|
CAGR 3-Years
31%
|
CAGR 5-Years
25%
|
CAGR 10-Years
42%
|
|
Telix Pharmaceuticals Ltd
ASX:TLX
|
Revenue
AU$502.5m
|
CAGR 3-Years
359%
|
CAGR 5-Years
381%
|
CAGR 10-Years
N/A
|
|
PYC Therapeutics Ltd
ASX:PYC
|
Revenue
AU$21.5m
|
CAGR 3-Years
99%
|
CAGR 5-Years
377%
|
CAGR 10-Years
32%
|
See Also
What is CSL Ltd's Revenue?
Revenue
14.2B
USD
Based on the financial report for Dec 31, 2023, CSL Ltd's Revenue amounts to 14.2B USD.
What is CSL Ltd's Revenue growth rate?
Revenue CAGR 10Y
10%
Over the last year, the Revenue growth was 21%. The average annual Revenue growth rates for CSL Ltd have been 12% over the past three years , 11% over the past five years , and 10% over the past ten years .